Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with...

Area of Science:

• Oncology
• Clinical Trials
• Patient-Reported Outcomes

Background:

• Existing research explores the link between patient-reported outcomes (PROs) and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC).
• This study specifically investigates this association in advanced NSCLC patients receiving first-line cemiplimab-based therapy.

Purpose of the Study:

• To evaluate the association between post-baseline PROs and OS in advanced NSCLC patients treated with cemiplimab.
• To determine if improvements in quality of life predict survival outcomes.

Main Methods:

• Analysis of PRO data from two Phase III clinical trials (EMPOWER-Lung 1 and EMPOWER-Lung 3).
• Utilized Cox proportional hazards models and landmark analyses at 3, 6, 9, and 12 months.
• Employed time-dependent analyses assessing change from baseline PROs as a covariate for OS.

Main Results:

• At 3 months, stable/improved global health status/quality of life (GHS/QoL) showed a 56% reduction in mortality risk (HR=0.44).
• Consistent results were observed at 6, 9, and 12-month landmarks.
• Every 10-point GHS/QoL improvement correlated with a 31% decreased risk of death (HR=0.69).

Conclusions:

• Improvements in post-baseline PROs, particularly GHS/QoL, are significantly associated with improved OS in advanced NSCLC patients on first-line cemiplimab.
• These findings support the use of PROs as important endpoints in clinical trials for advanced NSCLC.
• Results may guide endpoint selection and interpretation in future oncology trials.